Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Clinical Trial to Evaluate the Effects of Glow Shakes Premium Collagen Meal Replacement on Nutritional Adequacy, Body Composition, Skin Health, Satiety, and Overall Wellness in Adults Using GLP-1 or Dual-Incretin Medications for Weight Management

12 novembre 2026 aggiornato da: The Collagen Co. - GLP-1 Users

This is a single-group, open-label, decentralized clinical trial evaluating the effects of 12 weeks of once-daily consumption of Glow Shakes Premium Collagen Meal Replacement on nutritional adequacy, body composition, skin health, satiety, and overall wellness in 40 adults aged 18-55 years who are currently using a GLP-1 receptor agonist or dual-incretin medication for weight management. All study activities are conducted remotely; participants complete questionnaire assessments and smart scale body composition measurements at home at Baseline, Week 4, Week 8, and Week 12.

Participants replace a typical meal once daily with the study product for 12 consecutive weeks while continuing their existing GLP-1 or dual-incretin medication. The primary objective is to evaluate within-participant change in perceived nutritional adequacy from Baseline to Week 12. Secondary objectives include changes in body fat percentage, muscle mass, perceived skin health, hunger and satiety, hair health, energy and cognitive focus, nail health, gut comfort, metabolism support, physical strength, and product tolerability and satisfaction.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

40

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89101
        • Citruslabs

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Adults aged 18-55 years at the time of enrollment.
  • Currently using a GLP-1 receptor agonist or dual-incretin medication for weight management (e.g., semaglutide, tirzepatide, liraglutide) for a minimum of 4 weeks at the time of enrollment, with a stable or documented dose (no dose change within the 4 weeks prior to enrollment).
  • Self-reported interest in supporting weight management, lean muscle maintenance, nutritional adequacy, or beauty-related benefits (e.g., skin, hair, nails) during GLP-1 therapy.
  • Willing and able to use Glow Shakes Premium Collagen Meal Replacement as a once-daily meal replacement (replacing a typical meal) for 12 consecutive weeks and to complete all questionnaire assessments and Withings smart scale body composition measurements at Baseline, Week 4, Week 8, and Week 12.
  • Willing and able to maintain current GLP-1 or dual-incretin medication dose throughout the study duration without planned dose adjustments (except in the event of a medically indicated change).
  • Willing to maintain current diet (except for the study product), exercise routine, and lifestyle habits for the duration of the 12-week study, without introducing any new supplements or products specifically targeting weight loss, appetite, or body composition.
  • In good general health.
  • Resides in the United States.

Exclusion Criteria:

  • Pregnant or breastfeeding at the time of enrollment, or planning to become pregnant during the 12-week study period.
  • Known allergy or intolerance to any ingredient in the Glow Shakes formulation, including milk, whey, or collagen-derived ingredients.
  • Diagnosed with a serious medical condition requiring medical nutritional management, including but not limited to Type 1 diabetes, active cancer, or severe renal or hepatic disease.
  • Currently testing, or plan to in the next 12 weeks, a product for another research study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Glow Shakes Premium Collagen Meal Replacement Arm

Participants will consume one serving once daily - replacing a typical meal such as breakfast or lunch - for 12 consecutive weeks. One serving is prepared by adding the powder to 11.8 fl oz (approximately 350 mL) of water: add water first, then two scoops of powder, and shake for fewer than 10 seconds. Drink immediately after preparation.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Perceived Nutritional Adequacy
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived nutritional adequacy assessed via self-report questionnaire

Baseline to Week 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Body Fat Percentage
Lasso di tempo: Baseline to Week 12

Within-participant change in body fat percentage (%) measured by participant self-administered Withings smart scale

Baseline to Week 12
Change in Muscle Mass
Lasso di tempo: Baseline to Week 12

Within-participant change in muscle mass (kg) measured by participant self-administered Withings smart scale

Baseline to Week 12
Change in Self-Reported Weight Management and Food Cravings
Lasso di tempo: Baseline to Week 12

Within-participant change assessed via the validated Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)

Baseline to Week 12
Change in Self-Reported Perceived Skin Smoothness
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived skin smoothness score assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Perceived Skin Elasticity
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived skin elasticity score assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Hunger Intensity
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived hunger intensity assessed via visual analogue scale or equivalent validated hunger/satiety instrument

Baseline to Week 12
Change in Self-Reported Satiety Duration
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived satiety duration assessed via visual analogue scale or equivalent validated hunger/satiety instrument

Baseline to Week 12
Change in Self-Reported Food Craving Scores
Lasso di tempo: Baseline to Week 12

Within-participant change in food craving scores assessed via the Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)

Baseline to Week 12
Change in Self-Reported Hair Thickness
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived hair thickness assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Hair Health
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived hair health assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Energy Levels
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived energy levels assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Cognitive Focus
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived cognitive focus assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Nail Thickness
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived nail thickness assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Nail Health
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived nail health assessed via self-report questionnaire

Baseline to Week 12
Change in Gut Comfort and Digestive Health
Lasso di tempo: Baseline to Week 12

Within-participant change in gut comfort and digestive symptom scores assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Metabolism Support
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived metabolism support assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Physical Strength
Lasso di tempo: Baseline to Week 12

Within-participant change in perceived physical strength assessed via self-report questionnaire

Baseline to Week 12
Product Tolerability and Participant Satisfaction
Lasso di tempo: Week 12

Participant-reported product satisfaction, acceptability, and tolerability assessed via product satisfaction questionnaire

Week 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 gennaio 2027

Completamento dello studio (Stimato)

1 gennaio 2027

Date di iscrizione allo studio

Primo inviato

12 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi